Baxter Biopharma Solutions Announces Novavax COVID-19 Vaccine Sterile Manufacturing Agreement

Baxter International Inc. (NYSE: BAX), a global leader in sterile medication production and delivery, today announced that Baxter BioPharma Solutions has entered into an agreement to provide sterile manufacturing services for NVX-CoV2373, Novavax’ COVID-19 recombinant nanoparticle vaccine candidate with Matrix-M™ adjuvant. Baxter BioPharma Solutions is a premier contract manufacturing organization...
Read more...

;